It functions as a highly selective agonist of FXR, exhibiting 100-fold higher potency than endogenous bile acids, and it is currently the only agent recommended as a second-line treatment for PBC patients with UDCA tolerance and/or non-response to UDCA by the FDA [105]. This evidence concerns the gene NR1H4 and primary biliary cholangitis.